NCT01154933

Exeantide in Type 2 Diabetes on Insulin

The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University at Buffalo · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	exenatide 5 mcg	exenatide 5 mcg
DRUG	exenatide 10 mcg	exenatide 10 mcg
DRUG	placebo	saline sq

Timeline

• Start date: 2008-04-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2010-07-01
• Last updated: 2022-10-06
• Results posted: 2022-10-06

Locations

1 site across 1 country: United States